Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity

7 Jan 2020

Abstract excerpt

Abstract Fusion genes can be oncogenic drivers in a variety of cancer types and represent potential targets for targeted therapy. The BRAF gene is frequently involved in oncogenic gene fusions, with fusion frequencies of 0.2%–3% throughout different cancers. However, BRAF fusions rarely occur in the same gene configuration, potentially challenging personalized therapy design. In particular, the impact of the wide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31911540
DOI: 10.1158/1541-7786.mcr-19-0529

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF ActivityPMID 31911540Read ↗

BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.Semantic proximity Read ↗

Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer typesSemantic proximity Read ↗

Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of CancerSemantic proximity Read ↗

Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screeningSemantic proximity Read ↗

Molecular and clinicopathological characteristics of EGFR gene fusions in 35,023 Chinese patients with solid tumorsSemantic proximity Read ↗

Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome.Semantic proximity Read ↗

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.Semantic proximity Read ↗

Novel BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakersSemantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsSemantic proximity Read ↗

Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcomeSemantic proximity Read ↗

CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profilesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.